VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder
ZUG, Switzerland I June 22, 2017 I Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for VEYVONDI to prevent and treat bleeding episodes and peri-operative bleeding in adults (age 18 and older) diagnosed with von Willebrand Disease (VWD), the most common inherited bleeding disorder. Currently available in the U.S. as VONVENDI® [von Willebrand factor (Recombinant)], VEYVONDI is the first and only recombinant von Willebrand factor (rVWF) treatment for adults living with VWD.[1],[2],[3]
“With its clinical profile and physiology, VEYVONDI is a first-of-its-kind treatment for VWD,” said Alice Dietrich, MD, Head of Global Medical Affairs, Shire. “We’re deeply committed to advancing standards of care and outcomes for VWD patients worldwide, and today’s submission marks an important milestone in our efforts to address needs of patients living with VWD and make VEYVONDI available to more patients who could benefit from its use.”
Patients with VWD have a deficiency or dysfunction of VWF, a blood protein required for proper clotting.[4] Because of this, the blood does not clot properly, which may result in heavy menstrual periods, easy bruising, or frequent nose bleeds.[4] VEYVONDI is an innovative VWF replacement therapy produced and formulated without the addition of any exogenous raw materials of human or animal origin, resulting in a product that contains only trace amounts of FVIII.[2] This provides physicians with the flexibility to manage VWF levels.[3]
VEYVONDI was studied in patients, 18 to 64 years of age, in a multi-center, open label, non-randomized study assessing safety, efficacy and pharmacokinetics, with and without rFVIII.[2],[3] It was also studied in patients, 18 years and older, in a prospective, uncontrolled, international, multi-center, open label, non-randomized study assessing control of hemostasis before, during or after surgical procedures, with or without rFVIII.[5] The most common adverse reaction observed was generalized pruritus (itching).[3],[6] The EMA filing is based on data from these two Phase 3 clinical trials shared publicly in December 2015 and December 2016, respectively.
About von Willebrand disease (VWD)
VWD is the most common inherited bleeding disorder worldwide, affecting up to 1 percent of the world’s population.[7] VWD is caused by a deficiency or dysfunction of VWF, resulting in impaired blood clotting, and it affects women and men equally.[4],[8] The disease can manifest through various bleeding events, including heavy menstrual periods, easy bruising or frequent nose bleeds.[4] Bleeding caused by VWD is unpredictable and varies greatly among patients with the disease.[8] Many people with VWD may not know that they have it because their symptoms are mild or change over time.[9] Research shows that as many as 9 out of 10 people with VWD have not been diagnosed.[9]
About VONVENDI in the United States
VONVENDI was approved by the U.S. Food and Drug Administration (FDA) in December 2015 and is indicated for on-demand treatment and control of bleeding episodes in adults (18 years and older) with VWD.[1] VONVENDI is the first and only rVWF treatment developed for people living with VWD.[1] Shire is also seeking prophylaxis and pediatric indications for VONVENDI, with trials anticipated to conclude in 2019 and 2020, respectively. For more information on VONVENDI, please visit vonvendi.com.
VONVENDI [von Willebrand factor (Recombinant)] Important Information
Indication
VONVENDI [von Willebrand factor (Recombinant)] is a recombinant von Willebrand factor indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
SOURCE: Shire
Post Views: 291
VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder
ZUG, Switzerland I June 22, 2017 I Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for VEYVONDI to prevent and treat bleeding episodes and peri-operative bleeding in adults (age 18 and older) diagnosed with von Willebrand Disease (VWD), the most common inherited bleeding disorder. Currently available in the U.S. as VONVENDI® [von Willebrand factor (Recombinant)], VEYVONDI is the first and only recombinant von Willebrand factor (rVWF) treatment for adults living with VWD.[1],[2],[3]
“With its clinical profile and physiology, VEYVONDI is a first-of-its-kind treatment for VWD,” said Alice Dietrich, MD, Head of Global Medical Affairs, Shire. “We’re deeply committed to advancing standards of care and outcomes for VWD patients worldwide, and today’s submission marks an important milestone in our efforts to address needs of patients living with VWD and make VEYVONDI available to more patients who could benefit from its use.”
Patients with VWD have a deficiency or dysfunction of VWF, a blood protein required for proper clotting.[4] Because of this, the blood does not clot properly, which may result in heavy menstrual periods, easy bruising, or frequent nose bleeds.[4] VEYVONDI is an innovative VWF replacement therapy produced and formulated without the addition of any exogenous raw materials of human or animal origin, resulting in a product that contains only trace amounts of FVIII.[2] This provides physicians with the flexibility to manage VWF levels.[3]
VEYVONDI was studied in patients, 18 to 64 years of age, in a multi-center, open label, non-randomized study assessing safety, efficacy and pharmacokinetics, with and without rFVIII.[2],[3] It was also studied in patients, 18 years and older, in a prospective, uncontrolled, international, multi-center, open label, non-randomized study assessing control of hemostasis before, during or after surgical procedures, with or without rFVIII.[5] The most common adverse reaction observed was generalized pruritus (itching).[3],[6] The EMA filing is based on data from these two Phase 3 clinical trials shared publicly in December 2015 and December 2016, respectively.
About von Willebrand disease (VWD)
VWD is the most common inherited bleeding disorder worldwide, affecting up to 1 percent of the world’s population.[7] VWD is caused by a deficiency or dysfunction of VWF, resulting in impaired blood clotting, and it affects women and men equally.[4],[8] The disease can manifest through various bleeding events, including heavy menstrual periods, easy bruising or frequent nose bleeds.[4] Bleeding caused by VWD is unpredictable and varies greatly among patients with the disease.[8] Many people with VWD may not know that they have it because their symptoms are mild or change over time.[9] Research shows that as many as 9 out of 10 people with VWD have not been diagnosed.[9]
About VONVENDI in the United States
VONVENDI was approved by the U.S. Food and Drug Administration (FDA) in December 2015 and is indicated for on-demand treatment and control of bleeding episodes in adults (18 years and older) with VWD.[1] VONVENDI is the first and only rVWF treatment developed for people living with VWD.[1] Shire is also seeking prophylaxis and pediatric indications for VONVENDI, with trials anticipated to conclude in 2019 and 2020, respectively. For more information on VONVENDI, please visit vonvendi.com.
VONVENDI [von Willebrand factor (Recombinant)] Important Information
Indication
VONVENDI [von Willebrand factor (Recombinant)] is a recombinant von Willebrand factor indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
SOURCE: Shire
Post Views: 291
